SCHEMBL28299166

SCHEMBL28299166

NS(=O)(=O)Nc1cccc(NCC2CCOCC2)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.47
KCNH3 Q9ULD8 1/20 0.44
CA2 P00918 4/20 0.40
CA1 P00915 3/20 0.40
CSF1R P07333 1/20 0.40
KDR P35968 1/20 0.39
VNN1 O95497 1/20 0.37
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
EGLN2 Q96KS0 1/20 0.36
RORC P51449 1/20 0.36
LRRK2 Q5S007 1/20 0.35
SCN5A Q14524 1/20 0.34
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
CRHR1 P34998 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28299165 0.84 CA2 (0.50) CNR2KCNH3CA2CA1KDM4E
SCHEMBL13605313 0.79 KCNH3 (0.49) CNR2KCNH3CSF1RKDRVNN1
SCHEMBL21259117 0.75 KCNH3 (0.46) CNR2KCNH3CSF1RKDRVNN1
SCHEMBL2482925 0.74 CNR2 (0.48) CNR2CA2CA1RORC
SCHEMBL5793778 0.74 KCNH3 (0.65) CNR2KCNH3CSF1RKDRKDM4E
SCHEMBL31480204 0.74 AKR1C3 (0.51) CNR2KCNH3VNN1KDM4ECRHR1
SCHEMBL27991145 0.73 CA2 (0.52) CA2CA1
SCHEMBL1238863 0.70 MEN1 (0.57) CA2CA1PTGS2
Sulfanilamide SCHEMBL1955933 0.70 CA2 (0.47) CNR2CA2CA1TDP1RORC
SCHEMBL30078451 0.69 RORC (0.48) CNR2KCNH3CA2CA1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109966294-A Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases 艾伯维爱尔兰无限公司 2019-07-05 CN disclosed
CN-109897038-A Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases 艾伯维爱尔兰无限公司 2019-06-18 CN disclosed